Free Trial
OTCMKTS:BIOVF

Swedish Orphan Biovitrum (BIOVF) Stock Price, News & Analysis

Swedish Orphan Biovitrum logo
$33.30 0.00 (0.00%)
As of 10/16/2025

About Swedish Orphan Biovitrum Stock (OTCMKTS:BIOVF)

Advanced

Key Stats

Today's Range
$33.30
$33.30
50-Day Range
$28.97
$33.30
52-Week Range
$25.80
$33.30
Volume
N/A
Average Volume
10 shs
Market Capitalization
$11.85 billion
P/E Ratio
27.98
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIOVF Stock News Headlines

Sobi Increases Common Shares and Votes
Gold surges past $3,600 … but this has beat gold by 1,000x
Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.tc pixel
Swedish Orphan Biovitrum AB (publ) - Special Call
Is Sobi Set for a Rebound After Shares Drop 16% in 2024?
Sobi has completed issues of class C shares
See More Headlines

BIOVF Stock Analysis - Frequently Asked Questions

Swedish Orphan Biovitrum's stock was trading at $27.66 at the beginning of the year. Since then, BIOVF shares have increased by 20.4% and is now trading at $33.30.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) released its quarterly earnings data on Wednesday, July, 16th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.06. The firm had revenue of $649.61 million for the quarter, compared to the consensus estimate of $644.68 million. Swedish Orphan Biovitrum had a trailing twelve-month return on equity of 11.67% and a net margin of 16.05%.

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
7/16/2025
Today
10/17/2025
Next Earnings (Estimated)
10/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
N/A
Current Symbol
OTCMKTS:BIOVF
CIK
N/A
Fax
N/A
Employees
1,937
Year Founded
2010

Profitability

EPS (Trailing Twelve Months)
$1.19
Trailing P/E Ratio
27.98
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$367.52 million
Net Margins
16.05%
Pretax Margin
18.72%
Return on Equity
11.67%
Return on Assets
6.34%

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
1.00
Quick Ratio
0.66

Sales & Book Value

Annual Sales
$2.46 billion
Price / Sales
4.81
Cash Flow
$2.05 per share
Price / Cash Flow
16.23
Book Value
$10.71 per share
Price / Book
3.11

Miscellaneous

Outstanding Shares
356,000,000
Free Float
N/A
Market Cap
$11.85 billion
Optionable
Not Optionable
Beta
0.49

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (OTCMKTS:BIOVF) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners